Abstract:Background: Epilepsy is a complex chronic disease of the nervous system which influences the health of approximately 70 million patients worldwide. In the past few decades, despite the development of novel antiepileptic drugs, around one-third of patients with epilepsy have developed drug-resistant epilepsy. We performed a bioinformatic analysis to explore the underlying diagnostic markers and mechanisms of drug-resistant epilepsy. Methods: Weighted correlation network analysis (WGCNA) was applied to genes in epilepsy samples downloaded from the Gene Expression Omnibus database to determine key modules. The least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) algorithms were used to screen the genes resistant to carbamazepine, phenytoin, and valproate, and sensitivity of the three-class classification SVM model was verified through the receiver operator characteristic (ROC) curve. A protein–protein interaction (PPI) network was utilized to analyze the protein interaction relationship. Finally, ingenuity pathway analysis (IPA) was adopted to conduct disease and function pathway and network analysis. Results: Through WGCNA, 72 genes stood out from the key modules related to drug resistance and were identified as candidate resistance genes. Intersection analysis of the results of the LASSO and SVM-RFE algorithms selected 11, 4, and 5 drug-resistant genes for carbamazepine, phenytoin, and valproate, respectively. Subsequent union analysis obtained 17 hub resistance genes to construct a three-class classification SVM model. ROC showed that the model could accurately predict patient resistance. Expression of 17 hub resistance genes in healthy subjects and patients was significantly different. The PPI showed that there are six resistance genes ( CD247 , CTSW , IL2RB , MATK , NKG7 , and PRF1 ) that may play a central role in the resistance of epilepsy patients. Finally, IPA revealed that resistance genes ( PRKCH and S1PR5 ) were involved in “CREB signaling in Neurons.” Conclusion: We obtained a three-class SVM model that can accurately predict the drug resistance of patients with epilepsy, which provides a new theoretical basis for research and treatment in the field of drug-resistant epilepsy. Moreover, resistance genes PRKCH and S1PR5 may cooperate with other resistance genes to exhibit resistance effects by regulation of the cAMP-response element-binding protein (CREB) signaling pathway.

Case analysis of one epilepsy patients with severe drug eruption

Drug-induced Exfoliative Dermatitis: Literature Analysis of 240 Cases

Reintroduction of Oxcarbazepine after Allergic Reaction in Two Pediatric Patients with Epilepsy

Analysis on Causative Drugs of 1883 Drug Eruptions in a Hospitalized Population

A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system

Relationship between clinical features of intractable epilepsy in children and the single nucleotide polymorphisms of CYP3A41G

Pharmaceutical care for a child with epilepsy by clinical pharmacists

Analysis and Construction of a Molecular Diagnosis Model of Drug-Resistant Epilepsy Based on Bioinformatics

[Clinical Application of New Antiepileptic Drugs].

An Investigation of the Characteristics of Outpatients with Epilepsy and Antiepileptic Drug Utilization in a Multicenter Cross-Sectional Study in China

Case Report: A Case of Concomitant Paroxysmal Kinesigenic Dyskinesia and Epilepsy: Can We Treat Two Birds with One Stone?

Application of proteomic approaches to assess the effect of anti-epileptic drug on seizure foci

Literature analysis of non-steroidal anti-inflammatory drugs induced severe drug eruptions

Genetic Literacy Series: Clinical Application of Pharmacogenetics for Adverse Reactions to Antiepileptic Drugs

Network Pharmacology Analysis of Anticonvulsant Effect of Xiao Chai Hu Tang

HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema

Analysis of 101 Epidermolysis Bullosa Type Eruption Cases

Genotype-driven therapeutics in DEE and metabolic epilepsy: navigating treatment efficacy and drug resistance

Case analysis of individualized tacrolimus treatment on patient with nephrotic syndrome

Genetic Literacy Series: Clinical Application Of Pharmacogenetics For Adverse Reactions To Antiepileptic Drugs An Ilae Commission Review

Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients